PUBLISHER: DelveInsight | PRODUCT CODE: 1147346
PUBLISHER: DelveInsight | PRODUCT CODE: 1147346
Genital Herpes - Epidemiology Forecast - 2032
DelveInsight's 'Genital Herpes disease - Epidemiology Forecast to 2032' report delivers an in-depth understanding of Genital Herpes, historical and forecasted epidemiology in the 8MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.
Geography Covered:
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
- China
Study Period: 2019-2032.
Genital Herpes understanding
The DelveInsight's Genital Herpes epidemiology report gives a thorough understanding of Genital Herpes by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Genital Herpes is a chronic sexually transmitted infection (STI) characterized by recurrent, self-limited genital ulcers caused by herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2). It can cause blisters and open sores (lesions) in the genital area, but it can also be asymptomatic, meaning a person does not show symptoms.
Genital herpes can be asymptomatic or have mild symptoms that go unrecognized. When symptoms occur, genital herpes is characterized by one or more genital or anal blisters or ulcers. Additionally, symptoms of a new infection often include fever, body aches, and swollen lymph nodes. After an initial episode, which can be severe, symptoms may recur. Genital herpes caused by HSV-1 typically does not recur frequently. With HSV-2, recurrent symptoms are common; however, recurrences are often less severe than the first episode and tend to decrease over time. The laboratory diagnosis of acute genital HSV infection or asymptomatic virus shedding is made via direct viral detection. The method of choice is the demonstration of viral genomes in the skin or mucous membrane swabs using the polymerase chain reaction (PCR). It is rightly regarded as the gold standard of diagnosis in many laboratories.
Genital Herpes Epidemiology
The Genital Herpes epidemiology division provides insights about historical and current Genital Herpes patient pool and forecasted trends for every eight major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Genital Herpes epidemiology scenario in the 8MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), Japan, and China from 2019 to 2032.
In 2021, the total diagnosed Genital Herpes cases per year was 1.6 million cases in the 8MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Genital Herpes epidemiology [segmented as Prevalent HSV infected cases, Symptomatic Genital Herpes cases per year, Gender-specific cases of Genital Herpes, Diagnosed Genital Herpes cases per year, Total recurrent cases of Genital Herpes, and Treated patient pool of Genital Herpes] in the 8MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan and China from 2019 to 2032.
Country Wise- Genital Herpes Epidemiology
The epidemiology segment also provides the Genital Herpes epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.
KOL- Views
To keep up with the current Genital Herpes patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Genital Herpes domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
Scope of the Report:
- The report covers a descriptive overview of Genital Herpes, explaining its causes, symptoms, pathophysiology, and genetic basis.
- The report provides insight into the 8MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.
- The report assesses the selected cancer types risk and burden and highlights the unmet needs of Genital Herpes.
- The report helps to recognize the growth opportunities in the 8MM concerning the patient population.
- The report provides the segmentation of the Genital Herpes epidemiology by Prevalent HSV infected cases, Symptomatic Genital Herpes cases per year, Gender-specific cases of Genital Herpes, Diagnosed Genital Herpes cases per year, Total recurrent cases of Genital Herpes, and Treated patient pool of Genital Herpes in the 8MM.
Report Highlights:
- The companies and academics are working to assess challenges and seek opportunities that could influence Genital Herpes R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Genital Herpes.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Genital Herpes Report Key Strengths
- 11 Years Forecast
- 8MM Coverage
- Genital Herpes Epidemiology Segmentation
Key Questions
Epidemiology Insights:
- What are the key factors driving the epidemiology trend for eight major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China?
- What is the historical Genital Herpes patient pool in eight major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China?
- What would be the forecasted patient pool of Genital Herpes in eight major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China?
- Where will be the growth opportunities in the 8MM concerning the patient population about Genital Herpes?
- What are the key findings pertaining to the Genital Herpes epidemiology across the 8MM and which country will have the highest number of diagnosed Genital Herpes cases during the study period (2019-2032)?
- At what CAGR the patient population is expected to grow by 8MM during the forecast period (2019-2032)?
Reasons to buy:
- The report will help in developing business strategies by understanding trends shaping and driving the Genital Herpes market
- To understand the future market competition in the Genital Herpes market and Insightful review of the key unmet needs
- Organize sales and marketing efforts by identifying the best opportunities for Genital Herpes in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), Japan, and China.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Genital Herpes therapeutics in each of the markets covered
- To understand the future market competition in the Genital Herpes market
Table of Contents
1. Key Insights
2. Report Introduction
3. Genital Herpes Market Overview at a Glance
- 3.1. Market Share (%) Distribution of Genital Herpes in 2019
- 3.2. Market Share (%) Distribution of Genital Herpes in 2032
4. Executive Summary of Genital Herpes
- 4.1. Key Events
5. Epidemiology and Market Methodology
6. Disease Background and Overview
- 6.1. Introduction
- 6.2. Symptoms of Genital Herpes
- 6.3. Causes and Risk Factors of Genital Herpes
- 6.4. Pathophysiology of Genital Herpes
- 6.5. Stages of Genital Herpes
- 6.5.1. The prodrome stage
- 6.5.2. The blister stage
- 6.5.3. The ulcer stage
- 6.5.4. The healing stage
- 6.6. Genital Herpes Transmission and Infection
- 6.6.1. Primary herpes genitalis
- 6.6.2. Non-primary infections
- 6.6.3. Recurrent herpes genitalis
- 6.6.4. Asymptomatic genital viral shedding
- 6.6.5. Virus transmission
- 6.7. Complications of Genital Herpes
- 6.8. Diagnosis of Genital Herpes
- 6.8.1. Viral culture
- 6.8.2. Polymerase chain reaction (PCR) testing
- 6.8.3. Serologic testing
- 6.8.4. Diagnostic algorithm
- 6.8.5. Differential diagnosis
- 6.8.6. Diagnostic Guidelines
7. Treatment
- 7.1. First Clinical Episode
- 7.2. Episodic Therapy
- 7.3. Suppressive Therapy
- 7.4. Severe Disease
- 7.5. Other Therapies
- 7.6. Treatment Algorithm
- 7.7. Treatment Guidelines for Genital Herpes
- 7.7.1. WHO Guidelines for the Treatment of Genital HSV, 2016
- 7.7.2. 2015 CDC STD Guidelines on Herpes Infection
- 7.7.3. 2017 European Guidelines for the Management of Genital Herpes
8. Epidemiology and Patient Population
- 8.1. Key Findings
- 8.2. Assumptions and Rationale 8MM
- 8.3. Epidemiology Scenario in the 8MM
- 8.3.1. Prevalent HSV infected cases
- 8.3.2. Symptomatic Cases of Genital Herpes per year
- 8.3.3. Gender-specific Cases of Genital Herpes
- 8.3.4. Diagnosed Cases of Genital Herpes per Year
- 8.3.5. Total Recurrent cases of Genital Herpes
- 8.3.6. Treated Patient Pool of Genital Herpes
- 8.4. Epidemiology Scenario in the US
- 8.4.1. Prevalent HSV infected cases
- 8.4.2. Symptomatic Cases of Genital Herpes per year
- 8.4.3. Gender-specific Cases of Genital Herpes
- 8.4.4. Diagnosed Cases of Genital Herpes per Year
- 8.4.5. Total Recurrent cases of Genital Herpes
- 8.4.6. Treated Patient Pool of Genital Herpes
- 8.5. Epidemiology Scenario in the EU 5
- 8.5.1. Prevalent HSV infected cases
- 8.5.2. Symptomatic Cases of Genital Herpes per year
- 8.5.3. Gender-specific Cases of Genital Herpes
- 8.5.4. Diagnosed Cases of Genital Herpes per Year
- 8.5.5. Total Recurrent cases of Genital Herpes
- 8.5.6. Treated Patient Pool of Genital Herpes
- 8.6. Epidemiology Scenario in Japan
- 8.6.1. Prevalent HSV infected cases of Genital Herpes
- 8.6.2. Symptomatic Cases of Genital Herpes per year
- 8.6.3. Gender-specific Cases of Genital Herpes
- 8.6.4. Diagnosed Cases for Genital Herpes per Year
- 8.6.5. Total Recurrent cases of Genital Herpes
- 8.6.6. Treated Patient Pool of Genital Herpes
- 8.7. Epidemiology Scenario in China
- 8.7.1. Prevalent HSV infected cases of Genital Herpes
- 8.7.2. Symptomatic Cases of Genital Herpes per year
- 8.7.3. Gender-specific Cases of Genital Herpes
- 8.7.4. Diagnosed Cases of Genital Herpes per Year
- 8.7.5. Total Recurrent cases of Genital Herpes
- 8.7.6. Treated Patient Pool of Genital Herpes
9. Unmet Needs
10. Appendix
- 10.1. Acronyms and Abbreviations
- 10.2. Bibliography
- 10.3. Report Methodology
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight
List of Tables
- Table 1: Summary of Genital Herpes
- Table 2: Prevalent HSV infected cases (2019-2032) (in Thousands)
- Table 3: Symptomatic Cases of Genital Herpes per Year (2019-2032) (in Thousands)
- Table 4: Gender-specific Cases of Genital Herpes (2019-2032) (in Thousands)
- Table 5: Diagnosed Cases of Genital Herpes per Year (2019-2032) (in Thousands)
- Table 6: Total recurrent Cases of Genital Herpes (2019-2032) (in Thousands)
- Table 7: Treated Patient Pool of Genital Herpes (2019-2032) (in Thousands)
- Table 8: Prevalent HSV Infected Cases (2019-2032) (in Thousands)
- Table 9: Symptomatic Cases of Genital Herpes per Year (2019-2032) (in Thousands)
- Table 10: Gender-specific Cases of Genital Herpes (2019-2032) (in Thousands)
- Table 11: Diagnosed Cases of Genital Herpes per Year (2019-2032) (in Thousands)
- Table 12: Total recurrent Cases of Genital Herpes (2019-2032) (in Thousands)
- Table 13: Treated Patient Pool of Genital Herpes (2019-2032) (in Thousands)
- Table 14: Prevalent HSV Infected Cases (2019-2032) (in Thousands)
- Table 15: Symptomatic Cases of Genital Herpes per Year (2019-2032) (in Thousands)
- Table 16: Gender-specific Cases of Genital Herpes (2019-2032) (in Thousands)
- Table 17: Diagnosed Cases of Genital Herpes per Year (2019-2032) (in Thousands)
- Table 18: Total recurrent Cases of Genital Herpes (2019-2032) (in Thousands)
- Table 19: Treated Patient Pool of Genital Herpes (2019-2032) (in Thousands)
- Table 20: Symptomatic Cases of Genital Herpes (2019-2032) (in Thousands)
- Table 21: Gender-specific Cases of Genital Herpes (2019-2032) (in Thousands)
- Table 22: Diagnosed Cases of Genital Herpes per Year (2019-2032) (in Thousands)
- Table 23: Treated Cases of Genital Herpes (2019-2032) (in Thousands)
- Table 24: Prevalent HSV Infected Cases of Genital Herpes (2019-2032) ( in Thousands)
- Table 25: Symptomatic Cases of Genital Herpes per Year (2019-2032) (in Thousands)
- Table 26: Gender-specific Cases of Genital Herpes (2019-2032) (in Thousands)
- Table 27: Diagnosed Cases of Genital Herpes per Year (2019-2032) (in Thousands)
- Table 28: Total Recurrent Cases of Genital Herpes (2019-2032) ( in Thousands)
- Table 29: Treated Patient Pool of Genital Herpes (2019-2032) (in Thousands)
List of Figures
- Figure 1: Epidemiology and Market Methodology
- Figure 2: Understanding of Genital Herpes
- Figure 3: Symptoms of Genital Herpes
- Figure 4: Pathway of a Herpes Infection
- Figure 5: Diagnostic Algorithm of Genital Herpes
- Figure 6: Algorithm for the Treatment of Herpes in Immunocompromised Individuals
- Figure 7: Prevalent HSV infected cases in the 8MM (2019-2032)
- Figure 8: Symptomatic Cases of Genital Herpes per year in the 8MM (2019-2032)
- Figure 9: Gender-specific Cases of Genital Herpes in the 8MM (2019-2032)
- Figure 10: Diagnosed Cases of Genital Herpes per Year in the 8MM (2019-2032)
- Figure 11: Total Recurrent cases of Genital Herpes in the 8MM (2019-2032)
- Figure 12: Treated Patient Pool of Genital Herpes in the 8MM (2019-2032)
- Figure 13: Prevalent HSV infected cases in the US (2019-2032)
- Figure 14: Symptomatic Cases of Genital Herpes per year in the US (2019-2032)
- Figure 15: Gender-specific Cases of Genital Herpes in the US (2019-2032)
- Figure 16: Diagnosed Cases of Genital Herpes per Year in the US (2019-2032)
- Figure 17: Total Recurrent cases of Genital Herpes in the US (2019-2032)
- Figure 18: Treated Patient Pool of Genital Herpes in the US (2019-2032)
- Figure 19: Prevalent HSV infected cases in the EU 5 (2019-2032)
- Figure 20: Symptomatic Cases of Genital Herpes per year in the EU 5 (2019-2032)
- Figure 21: Gender-specific Cases of Genital Herpes in the EU 5 (2019-2032)
- Figure 22: Diagnosed Cases of Genital Herpes per Year in the EU 5 (2019-2032)
- Figure 23: Total Recurrent cases of Genital Herpes in the EU 5 (2019-2032)
- Figure 24: Treated Patient Pool of Genital Herpes in the EU 5 (2019-2032)
- Figure 25: Prevalent HSV infected cases of Genital Herpes in Japan (2019-2032)
- Figure 26: Symptomatic Cases of Genital Herpes per year in Japan (2019-2032)
- Figure 27: Gender-specific Cases of Genital Herpes in Japan (2019-2032)
- Figure 28: Diagnosed Cases of Genital Herpes per Year in Japan (2019-2032)
- Figure 29: Total Recurrent cases of Genital Herpes in Japan (2019-2032)
- Figure 30: Treated Cases of Genital Herpes in Japan (2019-2032)
- Figure 31: Prevalent HSV infected cases of Genital Herpes in China (2019-2032)
- Figure 32: Symptomatic Cases of Genital Herpes per year in China (2019-2032)
- Figure 33: Gender-specific Cases of Genital Herpes in China (2019-2032)
- Figure 34: Diagnosed Cases of Genital Herpes per Year in China (2019-2032)
- Figure 35: Total Recurrent cases of Genital Herpes in China (2019-2032)
- Figure 36: Treated Patient Pool of Genital Herpes in China (2019-2032)
